All states and territories had more than 15% of adults who were physically inactive and this estimate ranged from 17.3 to 47.7%, according to new state maps of adult physical inactivity prevalence released today by the Centers for Disease Control and Prevention (CDC).
Dr. Jack Cush reviews the journal reports and news from RheumNow.com.
Be sure to register for RheumNow Live 3/13/2020 in Fort Worth
Rheumnow.live.
Dr. John Cush RheumNow
6 years 9 months ago
MIRROR OL study shows that when pegloticase is co-administered with methotrexate, a high rate of response is seen (79% or 11/14 pts), achieved a complete response (sUA < 6 mg/dL) at Month 6. Topline results announced by Horizon. https://t.co/PY61xSoaxY
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for acute or chronic arthritis, headache, visceral pain, postoperative pain, etc but come with a small but significant risk of serious adverse effects, including hypertension, cardiovascular disease, kidney injury and GI complications.
Dr. John Cush RheumNow
6 years 9 months ago
Study of 224 pregnancies (133 women) w/ UCTD, ANA+, <45 yrs. The outcomes: live births 79%, 20% miscarriages, 0.9% stillbirths and 2.7% intrauterine growth restriction. Miscarriages & stillbirths strongly associated with aPL and ENA antibodies (P < 0.05). https://t.co/pvtneDW5In
NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.
The Journal of Neurology, Neurosurgery & Psychiatry reports there is moderate evidence that six sleep disorders (insomnia, fragmentation, daytime dysfunction, prolonged latency, rapid eye movement sleep behaviour disorder and excessive time in bed) significantly increases the risk of cognitive disorders.Metanalysis of 51 previously published reports looked at sleep issues and cognitive health over time.
Do postmenopausal women, under age 65 years, need a baseline BMD testing? A JAMA Insights review suggests that the absolute risk of fracture is low in this group and that USPSTF guidelines should be considered - that we should be screening women younger than 65 years who are at increased risk of osteoporosis and we should be using a formal risk assessment tool to identify candidates for bone density testing.
Dr. John Cush RheumNow
6 years 9 months ago
Same-day discharge arthroplasty (usually w/in 4-8 hrs after surgery) may be a feasible, made possible by \minimally invasive surgery, tranexamic acid & multimodal analgesia. CMAJ review contraindications: Age >80yrs, cirrhosis, CKD, bleeding disorders https://t.co/KzO6faH3sw
Dr. John Cush RheumNow
6 years 9 months ago
Rifampin is safest! 2 RCTs of 6485 latent TB pts compared 9 mos of isoniazid vs 4 mos of rifampicin. RIF had half the adverse events compared to INH; roughly half the rate of rash (1.5% v 2.7%); No grade 3-4 hepatotoxicity w/ RIF, compared 6%) w/ INH https://t.co/i3eONh5wMk
Dr. John Cush RheumNow
6 years 9 months ago
NHANES survey shows that about 1 of 5 adolescents and 1 of 4 young adults have prediabetes; higher in males and the obese. https://t.co/tyebscVjkr
Dr. John Cush RheumNow
6 years 9 months ago
The modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) has been validated as the most widely used assessment of Xray progression in AS, correlating with measures of disease activity, spinal mobility & physical function (over 2-years) https://t.co/UqKSJ7SZDC
It began as many cases do: an ill patient, in the ICU, with signs and symptoms across several body systems, yet no clear unifying diagnosis on admission. With things stabilizing, the internal medicine hospital team on which I was serving as hospitalist that week assumed care of the patient. As the case unfolded – pulmonary infiltrates that could be hemorrhagic, renal dysfunction with proteinuria – rheumatic diseases rose in the differential.
Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).
